Tebentafusp-tebn

(Kimmtrak®)

Tebentafusp-tebn

Drug updated on 4/18/2024

Dosage FormInjection (subcutaneous; 100 mcg/0.5 mL in a single-dose vial)
Drug ClassBispecific gp100 peptide-HLA-directed CD3 T cell engagers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Tebentafusp-tebn (Kimmtrak) is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
  • The information was derived from a single systematic review/meta-analysis that provided comprehensive data comparing Kimmtrak's effectiveness and safety to other drugs used in treating this condition.
  • In terms of overall survival, tebentafusp-tebn outperformed combined immune checkpoint blockade (ICB), anti-PD-(L)1 antibody, chemotherapy, targeted therapies, and anti-CTLA-4 antibody treatments. It showed a median overall survival rate of 22.4 months compared to the next best option, combined ICB at 15.7 months.
  • However, progression-free survival rates were similar across all treatment groups, ranging from 2.7 to 3.4 months, indicating no significant advantage for any particular drug, including tebentafusp-tebn, in delaying disease progression.
  • The study specifically addressed patients with advanced stages of uveal melanoma but did not provide detailed subgroup considerations within this population type.
  • Safety profiles were not explicitly mentioned in the study reviewed; however, hazard ratios suggested that tebentafusp-tebn has a favorable profile, reducing the risk of death when compared against other treatments such as combined ICB using different statistical models like MAIC, 2SMAIC, and STC.

Product Monograph / Prescribing Information

Document TitleYearSource
Kimmtrak (tebentafusp-tebn) Prescribing Information.2022Immunocore Limited, Abingdon, United Kingdom

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines